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Summary 
B cell chronic lymphocytic leukemia (CLL) is a malignancy of the CD5 + B cells. Prior studies 
indicated that CLL B cells generally express immunoglobulin (Ig) V. and VL genes with little 
or no somatic mutations. However, a recent report indicated that V.251, one of three VH genes 
belonging to the VH5 subgroup (e.g., V.251, V.32, and V815), not only is frequently rearranged 
in this disease, but also has extensive and selective mutations when expressed by CLL B cells. 
The extent and nature of these mutations contrasts markedly from the low level of mutations 
noted in V.5  genes used by normal B cells or other Ig V genes found expressed in CLL.  To 
determine  whether  this  difference  reflects  a  unique  property  of  VH251 or  a  previously 
unrecognized subgroup of CLL, we examined for V.5 Ig gene rearrangements in leukemia cells 
from 68 patients that satisfied clinical  and diagnostic criteria for CD5 § B cell CLL. Southern 
blot hybridization studies with probes for V.251  and the J. locus revealed that only 7 (10%) 
of the 68  monoclonal CLL cell populations had undergone Ig gene rearrangement involving 
V.5 genes. Two (3%) were found to have functionally rearranged V.5 genes that shared >198% 
sequence homology with 5-2R1,  a V~251 gene isolated from a pre-B cell acute lymphocytic 
leukemia. The other five CLL (7%) had functionally rearranged V.5  genes that each shared 
t>99% nucleic acid sequence homology with a germline V.32 isolated from human sperm DNA. 
These data indicate that V8251 or V.32 also may be expressed by CD5 § CLL B cells with little 
or no somatic mutation. These findings contrast with a recently published study on V.5 gene 
expression in B CLL and contest the hypothesis that extensive somatic mutation is a common 
property of the V~5  genes used in  this  disease.  Further  work to  define the clinical and/or 
phenotypic characteristics of patients with leukemia cells that express mutated versus nonmutated 
Ig V genes may reveal subsets of CLL that possibly differ in their cytogenesis, etiopathogenesis, 
and/or clinical behavior. 
B  cell chronic lymphocytic leukemia (CLL) 1,  the most 
common adult leukemia in Western societies,  may be 
considered a malignancy of "B-1 B cells", formerly referred 
to as CD5 (or Lyl) B cells (for reviews see references 1 and 
2). Generally, the leukemia cells in this disease coexpress CD5, 
pan-B cell surface antigens and surface Ig. In addition, common 
B cell CLL may share additional characteristics with those 
of normal human B-1 B cells, such as the frequent produc- 
tion of polyreactive autoantibodies (3-5), expression of my- 
elomonocytic surface antigens (6-10),  low-level expression 
of CD20 (11, 12), or the ability to form rosettes with mouse 
erythrocytes (13,  14). 
We found that the leukemia cells from many CLL patients 
1 Abbreviations  used in this~per: CLL, chronic  lymphocytic  leukemia;  CRI, 
cross-reactive idiotype; FR, framework  region. 
express Ig that bear one or more autoantibody-associated  cross- 
reactive idiotypes (CRIs) (15-18).  Evaluation of the molec- 
ular basis for such CRIs revealed that each may be a serologic 
marker for expression of a conserved Ig V gene with limited 
or no somatic mutation (19-21).  In addition, we and others 
find that CLL B cells not selected for expression of a CRI 
also may express Ig V genes that share extensive homology 
(>97%) with other known germline Ig V genes (18, 22-26). 
Finally,  normal or malignant murine B-1 B cells generally 
also express restricted, if not unique, repertoires of Ig V genes 
that display little or no somatic mutation (27-30).  Collec- 
tively, these studies imply that B-1 B cell malignancies use 
restricted repertoires of Ig V genes that have not diversified 
substantially from the germline DNA. 
However, there is an apparent exception to this general- 
ization. Humphries et al. (31) noted that the leukemia cells 
from related CLL patients expressed extensively mutated Ig 
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noted that 30% of patients with B cell CLL have rearranged 
V. genes that belong to this subgroup. These same investi- 
gators examined 11 additional CLL B cell populations that 
also expressed Ig encoded by V.5 genes (32, 33). Since prior 
studies indicated that Ig V. genes of this small subgroup are 
highly conserved and nonpolymorphic (34), these investigators 
compared the primary nucleic acid sequences of the expressed 
VH genes with that of known V.5 genes. In 10 of 11 CLL, 
they found the expressed V.5  genes to differ substantially 
from those of known germline sequences. Importantly, non- 
conservative nucleic acid base differences were found clustered 
primarily in sequences encoding the Ig CDRs which form 
the pocket of the presumed Ig antigen-combining site. Such 
substitutions  often are  noted in Ig selected in an antigen- 
driven secondary immune response. Accordingly, it appears 
that these CLL express somatically mutated Ig V genes that 
have been selected for their ability to bind some unknown 
antigen(s). 
It is not certain whether these leukemias represent a dis- 
tinct subset of CLL or whether they express mutated Ig V 
gene because they use Ig V. genes of the V.5 subgroup. The 
V.5  gene  subgroup  is  relatively  small,  consisting  of only 
two functional genes (V.251 and V832) and one pseudogene 
(V.15)  (31,  35, 36).  The V,251  gene is distinctive in  that 
it is transcribed at relatively high levels in the germline non- 
rearranged configuration (36). Conceivably, such transcrip- 
tional activity could affect higher rates of Ig gene rearrange- 
ment and/or  somatic mutation  of this V. gene in CLL B 
cells or leukemia B cell precursors. Alternatively, despite also 
being CD5 + (32, 33), the CLL cells examined by these in- 
vestigators may constitute a discrete subset of chronic leukemia 
that differs from that of other B cell CLL in its physiology 
of Ig gene expression.  For these reasons, we decided to ex- 
amine  for V,5  gene rearrangements  in  the  leukemia  cells 
from 68 patients that satisfied diagnostic and clinical  criteria 
for B cell CLL. 
of DNA was digested with fivefold excess of restriction  enzyme 
in appropriate buffers and then loaded onto a 0.8% agarose gel 
(GIBCO BRL, Gaithersburg, MD). After electrophoresis for 660 
volt-hours, the size-separated DNA was transferred onto nylon for 
Southern blot hybridization with radiolabeled probes as described 
(35, 44). Final washing conditions consisted of two 20-min washes 
at 65~  in 0.2x  SSC in 0.1% NaDodgO4 (V,251 probe), or 0.1x 
SSC in  0.1%  NaDodSO4  (J. probe)  (lx  SSC, 0.15 M  NaC1/ 
0.015 M sodium citrate, pH 7.0). 
Probes and Oligonucleoticles.  The probe for V,251 consisted of 
a 1.0-kb XbaI/PstlI fragment of WS1 (35) that included most of 
the V.251 coding region along with a few hundred bp of the 5' 
flanking region.  The J. probe consisted of a 2.1-kb Sau3A frag- 
ment  spanning  the  genomic  DNA  of J.2  through J.6.  DNA 
probes were radiolabeled to asp act of 109 cpm//zg with a_[np] 
CTP (New England Nuclear, Boston, MA) via random hexamer 
priming  (45). Oligonucleotides and probes such as the V.5 third 
framework region (FR) probe (5' GCA GAC TTC TCC TCA GG 
3') and the B-globin internal probe (5' GCA GAC TTC TCC TCA 
GG 3') were synthesized as described (15). These probes were 5' 
end-hbeled using -y-[32p]ATP  and polynucleotide kinase to asp act 
of 2  x  107 cpm/pmol, as described (46). 
PCR Amplification of Genomic DNA.  1 #g of genomic DNA 
was amplified using the PCP, technique as described (44). Primers 
corresponding  to the sense strand of the leader sequence of the 
V.251  gene  (dGCGAATTCAAGCTTCAACCGCCATCCTC- 
GCC) and the antisense strand of a J. consensus sequence (dGG- 
CGAATTCACCTGAGGAGACRGTGACC) (R, G/A) were used 
to amplify V.5 genes that were juxtaposed to J. through Ig gene 
rearrangement. To control for template fidelity, PCR using oligo- 
nucleotides  dACACAACTGTGTTCACTAGC  and  dCAACTT- 
CATCCACGTTCACC was performed to amplify the ~-globin gene 
in the genomic DNA of all samples, as described (20). 
Cloning and DNA Sequencing.  The amplified DNA segments 
were digested with HindlII and EcoRI to cut the linkers incorpo- 
rated into  the oligonucleotide primers, purified and ligated into 
a HindlII/EcoRI-cut pUC19 vector (Bluescribe; Stratagene, La 
Jolla, CA) for transformation  of competent Escherichia coli, as de- 
scribed (44). Plasmids containing the insert were isolated for double- 
strand  (ds)DNA sequencing as described (47, 48). 
Materials  and Methods 
Patients.  Peripheral  blood samples were obtained from 68 pa- 
tients  fulfilling diagnostic  and  immunophenotypic  criteria  for 
common B cell CLL at the UCSD Medical Center, the Veteran's 
Administration Hospital, or the Scripps Clinic and Research Foun- 
dation (all in La Jolla, CA; 37-41). The median age of the patients 
was 63, ranging from 41 to 79 years. The patients were heteroge- 
neous with respect to clinical stage (ranging from Rai stage 0 to 
stage IV) and prior therapy for CLL. 52 (76%) of the patients were 
male, reflecting the known 5:2 male/female bias in the prevalence 
of common B cell CLL (42). Each patient is assigned a unique three- 
letter  identifier (listed in capital letters). 
Flow Cytometry.  Direct  immunofluorescence analyses of leu- 
kemia cells were performed using a flow cytometer  (FACScan~; 
Becton Dickinson & Co., San Jose, CA) as described (38). PE- or 
fluorescein-conjugated mAbs specific for CD20, CD19, or CD5, 
and their respective isotype control mouse IgG, were purchased 
from Becton Dickinson & Co. Other mAbs were as described (43). 
DNA Isolation and Southern Blotting.  Genomic DNA was iso- 
lated from the leukemia cells as described (44). A total of 10/zg 
Results 
Flow Cytometric Analyses.  Direct immunofluorescence anal- 
yses of the mononuclear cells from each subject substantiated 
the diagnosis of common B cell CLL, indicating that >70% 
(mean 92%, range 71-99%) of the lymphocytes in each blood 
sample coexpressed pan-B cell surface antigens,  CD5 and K 
or X L chains (data not shown). Of the 68 leukemia cell popu- 
lations studied, 39 (57%) expressed Ig K  L chains and 29 (43%) 
expressed ~  L chains. 
Southern Blot Analyses.  Genomic DNA isolated from each 
of the 68 samples was digested with BamHI and HindlII 
for Southern blot hybridization  analysis.  Hybridization  of 
filter-immobilized DNA with the radiolabeled J. probe re- 
vealed each to have monoclonal Ig gene rearrangements (Fig. 
1, and data not shown). 45 (65%) of the samples had two 
detectable J. gene rearrangements,  whereas the remaining 
23  samples  each  had  only one nongermline  J.  restriction 
fragment. 
Using  the  V.251  probe,  we  found  that  most  DNA 
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kemia cell DNA digested  with BamHl and HindlII 
restriction  enzymes  and hybridized  sequentially  with 
radiolabeled  probes for V,251 (lane  A) and human  J. 
region (lane  B). (Left)  The kb of the nonrearranged 
bands containing  V.251 (Z5 kb), VH32 (3.2 kb), and 
VH15 (1.5/1.4 kb). (~')  The rearranged VH5 gene 
identified  in each  lane  A of samples 2-7. The samples 
in each  lane  are: NOM (lane  1), HAN (lane  2), CAV 
(lane 3), HOW (lane  4), PET (lane 5), ANG (lane 
6), and KER (lane 7). 
samples had  the germline V.5  gene pattern  of placental 
DNA  (Fig.  1,  lane  1A,  and data  not  shown)  (31). The 
V,251, V.32, and V815 genes are contained in the 7.5-, 3.2-, 
and 1.4/1.5-kb  fragments, respectively (e.g., Fig. 1, lane LA 
[NOM]). These four bands were identified in 37 (54%)  of 
the 68 samples tested. In 26 (39%) of the samples, the 3.2-kb 
V832 gene fragment was not detected,  suggesting  that the 
germline V~32 genes  of both  alleles were lost,  possibly 
through Ig gene rearrangement. However, previous studies 
demonstrated that the germline DNA of many individuals 
actually lack this  3.2-kb  BamHI/HindlII V.32 restriction 
fragment (31). As such, the absence of  this band in these CLL 
DNA samples instead may be due to genetic polymorphism. 
In 7 (10%) of the 68 CLL DNA samples, we identified 
nongermline bands with the V.251 probe. In all cases, these 
nongermline  bands matched those detected using the human 
J. probe, arguing that V,5 genes within these CLL had un- 
dergone Ig gene rearrangement (Fig. 1). Two (3% of  the total) 
had rearranged  BamHI/HindlII fragments of 8.5 kb,  sug- 
gesting that these CLL samples each had a rearranged V.251 
juxtaposed to J~4 (e.g., Fig. 1, lane 2A [HAN]) (31). In the 
other five samples, we detected nongermline BamHI/HindlII 
fragments of 3.0-4.0 kb that matched rearranged bands that 
hybridized  with  the human J.  probe  (Fig.  1,  samples 3 
[CAV], 4 [HOW], 5 [PET], 6 [ANG], and 7 [KER]). How- 
ever, such BamHI/HindlII restriction  fragments should be 
too small to contain  a rearranged  V,251  gene juxtaposed 
with  any J,  gene segment,  unless  alternative  BamHI  or 
HindlII restriction sites were introduced into or around this 
gene through Ig gene rearrangement, somatic  mutation, 
and/or genetic polymorphism. More likely, these relatively 
small restriction fragments contain V.32 rearranged with ei- 
ther J,4 (HOW, Fig. 1, lane 4A), J.5 (ANG and KER, Fig. 
1, lanes 6/t and 7A) or JH6 (CAV and PET, Fig. 1, lanes  3A 
and 5A),  respectively. 
Sequence Analyses  of Rearranged V.5 Genes.  To examine 
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the V,5 genes juxtaposed to J. through Ig gene rearrange- 
ment, we performed the PCR on the genomic DNA from 
each of the 68 samples using primers corresponding to the 
sense strand of the V~251 leader and the antisense strand of 
a J,  consensus  sequence. We  found  that  only  the  CLL 
samples noted to have  V.5 gene rearrangements by Southern 
analyses yielded PCR products  that hybridized with either 
an oligonucleotide  corresponding  to the third FR of V.251 
or  the genomic V8251 probe  (data  not  shown).  On  the 
other hand, each of the 68 DNA samples yielded 112-bp gene 
fragments in control PCR using ~/-globin specific primers 
(data not shown).  Therefore,  the inability  to amplify V.5 
Ig gene rearrangements in the other DNA samples could not 
be ascribed to inadequate template quality or nonspecific  PCR 
inhibitors. 
Nucleic acid sequence analyses  confirmed that each of these 
seven CLL DNA samples contained rearranged  V~5 genes 
(Figs.  2 and 3).  The two CLL DNA samples reasoned to 
have possible V,251  gene  rearrangements  by  Southern 
(DOB and HAN) were found to have rearranged V,5 genes 
that shared i>98% sequence homology with 5-2R1, a Va251 
gene isolated from an acute pre-B cell leukemia (49) (Fig. 
2). The V. gene of DOB is identical to that of 5-2R1. The 
V. of HAN, on the other hand, differs from 5-2R1 by four 
nucleotides in the first Ig FR and two in the third Ig FR 
(Fig. 2). However, only two of these base differences  are non- 
conservative, resulting in a Gly -- Arg substitution at posi- 
tion 26 and a Ser -~ Arg change at position 82B (numbering 
according to Kabat et al.  [50]). The rearranged V.5 genes 
of the other five CLL (e.g., CAV, HOW, PET, ANG, and 
KER) were found to share i>99% nucleic acid sequence ho- 
mology to  a  germline VH32 gene  isolated  from  human 
sperm DNA (Fig. 2) (31, 51). Except for a conservative base 
change in the codon for the amino acid at position 7 in the 
first Ig FR,  CAV and HOW  are identical  to  VH32. The 
other three V. genes also differed from V.32 by one (PET) ..............  LEADER  ................... 
Set lhrA  I a I  I eLwuAI aLeuLeuLeuR  I aUul LeuG I n  I HTERUEH  I HG  SEQUEHCE- 
TCAACCGCCATCCTCGCCCTCCTCCTRGCTRTTCTCCRRGGT  CRGTCCTGCCGRGGGCTTGRGGTCRCRGR6GRGflRC*GGTGORRRGGRGCCCCTGATTCRRRTTT  UH251 
5-2RI 
OGB  ..........................  G' 
HRH  ..........................  G' 
UH32  ..............  T'G .........  G' 
CAU  ..........................  G' 
HGW  ..........................  G' 
PET  ..........................  G' 
AHG  ..........................  G" 
KER  ..........................  G' 
*'G  ........................................  '  ....  "G'"'  ............  '  ........... 
"G  ...................................  *o~  ............  "'  ......... 
G ...............................................  6 .........  C'R'T  .............. 
G ...............................................  G .........  C'R'T  .............. 
G ...............................................  G .........  C'A.T  .............. 
G ...............................................  G .........  C'R'TT  ............. 
G ...............................................  G .........  C'"  'TT ............. 
G ...............................................  G .........  C"  'TT ............. 
I  7  I0  17  20  26 
~y~a~Cy~a~uUa~nLeu~nS~y~u~LysLy~P~y~u$e~LeuLys~eSerCysLys~ySe~G~yTy~ 
UH251  T~T~TCTCCCCC~C~GG~GTCT~TGCCG~GGTGC~GCTG~TGC~TCTGG~C~G~T~GCCC~RGTCTCTGR~GRTCTCCT~T~GGTTCT~T~C 
5-2RI  ............................................................................................................ 
00~  ''''  ..............................................................  '  ..........  '''  .......  ''''  ................. 
HAH  .............................................................................  C  ........................  R  ....  T 
UH32  .......  T"AT  .................  A ....................................................  G  ......................... 
CRU  .......  T"RT  .................  R .................  C ..................................  G ...................  ;  ..... 
HOU  .......  T"RT  .................  R .................  C ..................................  G ......................... 
PET  .......  T"RT  .................  R .................  C ..................................  G ......................... 
RHG  .......  T"RT  .................  R .................  C ..................................  G ......................... 
KER  .......  T"RT  .................  R .................  C ..................................  G ......................... 
UH251 
5-2R1 
OOB 
HAH 
VH32 
CRV 
HOW 
PET 
ANG 
KER 
30 ......  COAl ......  40  50 ....................  COR2 .......  60 ....... 
~e~PheThrSePTyrTPp~eG~yT~pU~gG~nNeLPP~G~yLy~G~yLeuG~uTPp~eLG~y~e~eT~PPP~G~y~p~e~spThP~PgTyPSePPP~e~ 
~G~TTT~CC~GCT~CTGGRTcG~CT~GT~CGC~G~TGC~C~GG~RRGGCCTGGRGTG~TGGGG~TC~TCTRT~CT~TG~CTCT~AT~CC~RT~GCCc~TC~ 
''T' 
.....................  R .............................................  GG"TG  ....  A ........  T ......  AC ............ 
.....................  A .............................................  GG"TG  ....  A ........  T ......  RC ............ 
.....................  A .............................................  GG"T6  ....  A ........  T ......  RC ............ 
.....................  R .............................................  GG"TG  ....  R ........  T ......  RC ............ 
.....................  R .............................................  GG"TG  ....  R ........  T ......  RC ............ 
.....................  R .............................................  GG"TG  ....  R ........  l  ......  RC ............ 
.........  69  70  80  82B  90  94 
PhoG~nG~yG~nU~ThP~eSer~spLy~eP~eSerThPR~aTyrLeuG~nTPp~er~er~euLy~a~erRspThrRiaMe~TyrT~rCy~ia~Pg 
UHZSI  TTCC••GGCC•GGTC•C•ATCTC•GCCG•C•AGTCC•TCAGC•CCGCCT•CCTGC•GTGGAGC•GCCT•••GGCCTCGG•C•CCG•C•TGT•TT•CTGTGCGAG• 
5-2RI  .......................................................................................................... 
DOB  ......  ',  .................................................................................................. 
HAH  ..................  T ..............................................  G ....................................... 
UH32  ...........  C ..............  T .................  T ............................................................ 
CAU  ...........  C ..............  T .................  T ............................................................ 
HOW  ...........  C ..............  T .................  [  ............................................................ 
PET  ...........  C ..............  T .................  T ............................................................ 
AHG  ...........  C ..............  T .................  T ............................................................ 
KER  ...........  C ..............  T ..........  , .......  T ............................................................ 
Figure  2.  Nucleic acid sequences of rearranged V.5 genes and V.32 compared with VH251. The complete sequence of V.251  is provided (31). (*) 
Introduces  gaps to maximize sequence homologies among the compared  sequences. Above the V.251  sequence are the deduced amino acid sequence 
and descriptors indicating the leader sequence, the intervening sequence of the first intron, or the Ig CDR1 and CDR2. The numbers above the deduced 
amino acid sequence refer to the Ig amino  acid residues according  to Kabat et al. (50). Below the V.251  sequence are other V.5 genes, as indicated 
by the sequence names (left).  (-) Indicates homology with V.251  at a given nucleic acid base position. 
or two (ANG or KEk) base changes in the intron (marked 
intervening sequence, Fig.  2). 
Each  of the  rearranged  V.5  Ig  genes  detected  in  our 
survey had  a  unique  sequence  encoding the  third  CDR 
(CDR3) (Fig. 3). The CDR3 sequence of each had stretches 
with high homology to known germline D. and J, gene 
segments (50, 52). The sequences encoding the CDIk3 of 
PET, CAV, or HOW each had highest homology with DN1. 
Those of  DOB or KER had the highest homology  with Dxpl, 
whereas the CDR3 sequence  of HAN or ANG had the highest 
homology with DA4 or DK1, respectively. Of the seven dis- 
parate CDRs, we deduce that three (DOB, HOW, and HAN) 
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SerIleSerSerSerGlyTyrTyrSer 
DOB  TCGATCTCCAGTAGTGGTTATTACTCT 
Dxpl  "C  ......... 
AsnPheAspTyrTrpGlyGlnGlyThrLeuValThrValSerSer 
AACTTTGACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCT~  DOB 
T  ................... A ........................  JH  4 
GlnIleAlaGlyIleAlaAlaAlaGlyMetTrpGlyPro 
CAV  CAAATCGCCGGTATAGCAGCAGCTGGTATGTGGGGTCCA 
DNI  ................... 
TyrTyrTyrTyrTyrMetAspValTrpGlyLysGlyThrThrValThrValSerSer 
TACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCA  CAV 
............................. GC  ..........................  JH6 
GluGlnTrpLeuValLeuSer 
HOW  GAGCAGTGGCTGGTACTGTCC 
DNI  T  .....  CA  ........ 
AsnPheAspTyrTrpGlyGlnGlyThrLeuValThrValSerSer 
AATTTTGACTAC~CAGGGAACCCTGGTCACCGTCTCCTCA  HOW 
T-C  ................. A ........................  JH  4 
LeuTyrGlyAspPheSerThrVal 
HAN  C  TT  TACGGTGACT  TT  TC  TACAGTT 
DA4  ....... 
AspTyr  TrpGlyGl  nGlyThr  LeuVaiThrVal  Se  rSer 
GACTAC~CAGGGAACCC  TGGTCACCGTCTCCTCA  HAN 
..............  A ........................  JH4 
LeuLeuTyrGlyAlaAlaAlaAlaTrpGly 
PET  C  TATTGTATGGAGCAGCAGCTGCC ~ 
DNI  ........... 
TyrTyrTyrTyrTyrMetAspValTrpGlyLysGlyThrThrVaiThrValSerSer 
TAC  TAC  TACTAC  TACATGGAOG  TC  ~AAAGGGACAACGGTCACCGTCTCCTCA  PET 
............ GGT  .............. GC  .......  C ..................  JH6 
HisThrValGlyGlyTyrSerGlyCys 
ANG  CACACAGTGGGAGGATATAGTGGCTGT 
DKI  ............... 
SerGlnSerTrpGlyGlnGlyThrLeuValThrValSerSer 
TCCCAGTCC  ~  CAAGGAACCTTGGTCACC  GTCTCCTCA  ANG 
￿9  T-G-C  .................. C  .................  JH  5 
HisThrP  roGlnGlyProLeuTyrSer  PheAspSer  TrpGlyGlnGlyThrLeuVa iThrValSe  r  Set 
KER  CACAC  TCCCACAC  TG  TATTAC  TATGGG  TTCGACTCC  TGGGC4:CAAGGAACCCTGGTCACCGTCTCC TCA  KER 
Dxpl  ......................................................  JH  5 
Figure 3.  The sequences encoding the deduced CDR3 of each of the rearranged V.5 genes compared with germline D. and J. minigene sequences 
having the highest nucleic acid sequence  homology. All sequences  are identified (right and left). (N-D-N) Column of sequences  presumed to be generated 
from D. minigenes and N-sequence  insertions. (]H Segments) Column of sequences encoded by a rearranged J, minigene. Above  each sequence  is the 
deduced amino acid sequence. The germline D. and J, minigenes with highest nucleic acid sequence homology are listed below each sequence. (.) 
Indicates sequence homology. 
were encoded by J.4, two (ANG and KER) by JH5, and two 
(CAV and PET) by J.6  (Fig.  3). 
Discussion 
We examined the leukemia cells from 68 randomly selected 
patients  that  satisfied  clinical  and  diagnostic  criteria  for 
CD5 + B cell CLL. This group of CLL patients was noted 
to have a mean age and sex distribution comparable with that 
noted in earlier surveys of patients with this disease (39, 42). 
Furthermore, FACS  |  analyses demonstrated that the leukemia 
cells from each patient coexpressed pan-B cell surface antigens, 
CD5 and K or k Ig L chains. Of these CLL samples, we found 
that 7 (10%) had Ig gene rearrangements involving the V.5 
gene family.  Nucleic acid sequence analyses  of these Ig V. 
genes did not reveal evidence for intraclonal  diversity or Ig 
somatic mutations. Instead,  genetic polymorphism apparently 
accounts for some of the differences noted in V.5 genes de- 
tected in our survey. For example, the conservative base change 
in the codon at position 7 of the V.32 used by some of the 
CLL (Fig.  2) also was observed in the V,32 genes of two 
of three normal  individuals  examined by Sanz  et  al.  (34). 
Moreover, all V.5 genes detected in this survey shared >98% 
nucleic acid sequence homology with known or suspected 
germline genes. This paucity of substantial somatic diversifi- 
cation  in  the rearranged  V.5  genes noted in  this  study is 
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comparable with that of most other V. or VL genes found 
expressed in this disease (18-26). 
In contrast with previous reports on the V.5 genes rear- 
ranged in CLL (31), V.32 and not V~251 was the most fre- 
quently rearranged V.5 gene detected in our survey. Initially, 
V.32 was assumed to be a pseudogene due to a termination 
codon at amino acid position 82B (31, 35). However, Sanz 
et al.  (34) reexamined  the original  V.32 clones and found 
errors in the reported sequence, allowing these investigators 
to conclude that V.32 was in fact functional. The rearranged 
V.32 genes observed in the current survey also lack any ter- 
mination codons and appear functional. In view of the finding 
that  many individuals  apparently  lack  the  V.32  germline 
band,  the relatively frequent  use of V,32  in  CLL appears 
remarkable.  Indeed, the absence of the V.32 germline band 
may indicate that a relatively high proportion of individuals 
do not possess this Ig V gene in their germline DNA. How- 
ever, other explanations  are possible, including polymorphisms 
affecting  the  restriction  sites  in  and  around  V.32  and,  at 
least in the current  survey,  Ig gene rearrangements  and/or 
deletions by the leukemia cells  studied. 
In any case, it is unlikely that we failed to detect rearranged 
V.251  genes  in  our  survey  that  incurred  extensive  and 
selected somatic mutations. We performed Southern blot anal- 
yses using washing conditions that allow for detection of rear- 
ranged  V. genes that  share  >80%  homology with V.251. In addition, over half of the VH251 probe used in these anal- 
yses corresponded to the 5' flanking region and intron of the 
V.251 gene, regions not subject to selected Ig somatic mu- 
tation.  Furthermore,  using  the  V.251  probe we  detected 
both V,32 and V.15, V.5 genes having 95 and 86% coding 
region nucleic acid sequence homology with V.251, respec- 
tively. Finally,  PCR on all leukemia samples using oligonu- 
cleotides to amplify V.5 genes juxtaposed with J. demon- 
strated  that  only those DNA  samples that  had V.5  gene 
rearrangement by Southern also generated PCR products that 
hybridized with oligonucleotides or full-length DNA probes 
for V.251  and related V.5  genes. 
These results contrast markedly with those recently reported 
by Cai et al. (32, 33), indicating that highly mutated V.251 
genes frequently are expressed in human B cell CLL. Earlier 
reports indicated that VH251 gene may be rearranged in the 
leukemia cells of 30% of the patients with this disease (31). 
More importantly, nucleic acid sequence analyses revealed ex- 
tensive numbers of base substitutions from the putative germ- 
line VH251 sequence. Moreover, the noted pattern  of non- 
conservative base substitutions  in the V.251  gene used by 
these CLL B cells was typical of Ig V genes expressed in sec- 
ondary immune responses to antigen (32, 33). In contrast, 
we found that only 2 of 68 CLL cell samples use V.251, and 
that these two apparently express this gene with little or no 
somatic mutation. 
Such differences may reflect heterogeneity within what cur- 
rently is considered B cell CLL. Subgroups of CLL may exist 
that  arise from different B cell lineages and/or stages of B 
cell differentiation.  Such differences may be reflected in the 
Ig V genes used by each subgroup. Already, we have noted 
that CD5-  B cell CLL, in contrast with CD5 + B cell CLL, 
may display intraclonal diversity in their expressed Ig V genes 
(25, 53). Although both the current survey and that of Cai 
et al. (32, 33) examined CD5 + B cell CLL, there also may 
exist subgroups within this category of CLL that express Ig 
similar to that found in the primary (e.g., nonmutated) versus 
secondary (e.g.,  mutated)  humoral  immune  response.  Ar- 
guably, the leukemia cells in the former category may be those 
that express "natural" or polyreactive autoantibodies that fre- 
quently  are  detected in  CD5 + B  cell CLL (3-5).  On  the 
other hand,  those CLL in the latter category may originate 
from B cells previously selected to express Ig with affinity 
for some unknown environmental or self-antigen(s).  Antigen 
selection may not be unique to this subgroup, however. Re- 
cent Ig chain mixing studies employing murine transfectomas 
have indicated that  the polyreactive binding  activity of Ig 
encoded by nonmutated  Ig V  genes also may be a selected 
specificity (54). In addition, as demonstrated in this survey, 
it is not likely that the observed differences in the extent of 
observed Ig mutation depends upon expression of Ig V genes 
of the VH5 subgroup, in particular V.251. Rather, there may 
exist subsets of CD5 + B cell CLL that  have differences in 
their cytogenesis and/or etiopathogenesis. Comparison of B 
cell CLL that express nonmutated versus highly mutated Ig 
V genes may reveal features that can be used to discriminate 
between these two types of leukemias, possibly allowing us 
to define subsets of CLL that have different clinical  features 
and/or  therapeutic  requirements. 
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